The release of inflammatory cytokines from human peripheral blood mononuclear cells in vitro following exposure to adenovirus variants and capsid

Human Gene Therapy

Volumn 13, Issue 1, 2002, Pages 129-141

  Higginbotham, James N ^a,b   Seth, Prem ^b   Blaese, R Michael ^a,c   Ramsey, W Jay ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^b Iowa Cancer Research Foundation   (United States)

^c ValiGen Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA CHEMOKINE; BETA CHEMOKINE; CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; RECOMBINANT DNA; TUMOR NECROSIS FACTOR ALPHA; VIRUS VECTOR;

ADENOVIRUS 5; ARTICLE; CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; MONONUCLEAR CELL; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; PROTEIN INDUCTION; SIGNAL TRANSDUCTION; STIMULATION; STIMULUS RESPONSE; VIRION; VIRUS ACTIVATION; VIRUS CAPSID; VIRUS CONCENTRATION; VIRUS INACTIVATION; VIRUS RECOMBINANT;

ADENOVIRUSES, HUMAN; CAPSID; CELLS, CULTURED; CHEMOKINES, CXC; CHEMOTACTIC FACTORS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; GENETIC VECTORS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; GROWTH SUBSTANCES; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERLEUKINS; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; MACROPHAGE INFLAMMATORY PROTEIN-1; RANTES; TUMOR NECROSIS FACTOR-ALPHA;

ADENOVIRIDAE; HUMAN ADENOVIRUS TYPE 5;

EID: 0036149133     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430340152712683     Document Type: Article

References (69)

1. A phase I study of recombinant adenovirus vector-mediated intraperitoneal delivery of herpes simplex virus thymidine kinase (HSV-TK) gene and intravenous ganciclovir for previously treated ovarian and extraovarian cancer patients
2. Replication-deficient adenovirus induces expression of interleukin-8 by airway epithelial cells in vitro
3. Interleukins 6 and 11 protect mice from mortality in a staphylococcal enterotoxin-induced toxic shock model
4. Efficient, repeated adenovirus-mediated gene transfer in mice lacking both tumor necrosis factor alpha and lymphotoxin α
5. Gene therapy for cystic fibrosis using E1 deleted adenovirus: A phase I trial in the nasal cavity
6. Adenovirus infection stimulates the raf/MAPK signaling pathway and induces interleukin-8 expression
7. Interleukin-1 mediates a rapid inflammatory response after injection of adenoviral vectors into the brain
8. Protocol of gene therapy of the respiratory manifestations of cystic fibrosis using a replication deficient adenovirus to transfer the normal cystic fibrosis transmembrane conductance regulator cDNA to the airway epithelium
9. Transfer of genes to humans: Early lessons and obstacles to success
10. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis
11. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: Tolerization of factor IX and vector antigens allows for long-term expression
12. Adenovirus-mediated transfer of the CFTR gene to lung of nonhuman primates: Biological efficacy study
13. Leukemia inhibitory factor, interleukin 6, and other cytokines using the GP130 transducing receptor: Roles in inflammation and injury
14. A mouse model for investigating the molecular pathogenesis of adenovirus pneumonia
15. Transfer of the CFTR gene to the lung of nonhuman primates with E1-deleted, E2a-defective recombinant adenoviruses: A preclinical toxicology study
16. Elimination of both E1 and E2a from adenovirus vectors further improves prospects for in vivo human gene therapy
17. A new technique for the assay of infectivity of human adenovirus 5 DNA
18. Characteristics of a human cell line transformed by DNA from human adenovirus type 5
19. Lung-specific expression of adenovirus E3-14.7K in transgenic mice attenuates adenoviral vector-mediated lung inflammation and enhances transgene expression
20. Researchers and regulators reflect on first gene therapy death
21. Temperature-sensitive replication of H5ts125 adenovirus DNA in vitro
22. Isolation of deletion and substitution mutants of adenovirus type 5
23. The impact of developmental stage, route of administration and the immune system on adenovirus-mediated gene trasfer
24. A phase II trial with an E1B-deleted adenovirus, ONYX-015, in patients with recurrent, refractory head and neck cancer
25. Initiation of the acute phase response and synthesis of cytokines
26. Interleukin-8 mediates injury from smoke inhalation to both the lung endothelial and the alveolar epithelial barriers in rabbits
27. Inhibition of NF-kB activation in combination with Bcl-2 expression allows for persistence of first-generation adenovirus vectors in the mouse liver
28. Adenovirus-mediated expression of human coagulation factor IX in the rhesus macaque is associated with dose-limiting toxicity
29. Transformation of mammalian cells by constitutively active MAP kinase kinase
30. Expression of human interleukin-1 receptor antagonist in mouse lungs using a recombinant adenovirus: Effects on vector-induced inflammation
31. TNF-alpha receptor signaling and IL-10 gene therapy regulate the innate and humoral immune responses to recombinant adenovirus in the lung
32. Cytokines in adenoviral disease in children: Association of interleukin-6, interleukin-8, and tumor necrosis factor alpha levels with clinical outcome
33. Evaluation of the efficacy and safety of in vitro adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator cDNA
34. Acid-induced lung injury. Protective effect of anti-interleukin-8 pretreatment on alveolar epithelial barrier function in rabbits
35. A phase I study of intralesional administration of an adenovirus vector expressing the HSV-1 thymidine kinase gene (AdV.RSV.TK) in combination with escalating doses of ganciclovir in patients with cutaneous metastatic malignant melanoma
36. Inhibition of neutrophil-mediated acute inflammation injury by an antibody against interleukin-8
37. Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo
38. Gene transfer into the liver of nonhuman primates with E1-deleted recombinant adenoviral vectors: Safety of readministration
39. Toxicological comparison of E2a-deleted and first-generation adenoviral vectors expressing (α1-antitrypsin after systemic delivery
40. Nonspecific inflammation inhibits adenovirus-mediated pulmonary gene transfer and expression independent of specific acquired immune response
41. Pathogenesis of adenovirus type 5 pneumonia in cotton rats (Sigmodon hispidus)
42. Replication-defective recombinant adenovirus expressing the Epstein-Barr virus (EBV) envelope glycoprotein gp340/220 induces protective immunity against EBV-induced lymphomas in the cottontop tamarin
43. Adenovirus-mediated transfer of a recombinant α1-antitrypsin gene to the lung epithelium in vivo
44. In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium
45. Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF
46. Clinical evaluation of live, oral types 1, 2, and 5 adenovirus vaccines
47. Mechanism of enhancement of DNA expression consequent to cointernalization of a replication-deficient adenovirus and unmodified plasmid DNA
48. Adenovirus-mediated transfer of the CFTR gene to lung of non-human primates: Toxicity study
49. Interleukin-6 enhances a cellular activity that functionally substitutes for E1a protein in transactivation
50. NF-1L6, a member of the C/EBP family, regulates E1a responsive promoters in absence of E1a
51. A phase I study of adenovirus mediated gene transfer of interleukin 2 cDNA into metastatic breast cancer or melanoma
52. Chemokines in lung injury: Thomas A. Neff Lecture
53. Early-onset inflammatory responses in vivo to adenoviral vectors in the presence or absence of lipopolysaccharide-induced inflammation
54. 2is required for the lysis of adenovirus-infected cells by tumor necrosis factor
55. Immunization with live types 7 and 4 adenovirus vaccines. I. Safety, infectivity, antigenicity, and potency of adenovirus type 7 vaccine in humans
56. Immunization with live types 7 and 4 adenovirus vaccines. II. Antibody response and protective effect against acute respiratory disease due to adenovirus type 7
57. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors
58. Cystic fibrosis gene therapy using an adenovirus vector: In vivo safety, and efficacy in nasal epithelium
59. Phosphorylation within the transactivation domain of adenovirus E1A protein by mitogen-activated protein kinase regulates expression of early region 4
60. A phase I study of gene therapy of cystic fibrosis utilizing a replication deficient recombinant adenovirus vector to deliver the human cystic fibrosis transmembrane conductance regulator cDNA to the airways
61. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy
62. Inactivation of E2a in recombinant adenoviruses limits cellular immunity and improves the prospect for gene therapy of cystic fibrosis
63. MHC class I restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1 deleted recombinant adenoviruses
64. In vivo evaluation of the safety of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator cDNA to the lung
65. Specific inhibitors of p38MAP kinse
66. Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis
67. Inhibition of tumor necrosis factor alpha decreases inflammation and prolongs adenovirus gene expression in lung and liver